Breast Cancer
October 14, 2024
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
The ASCO Post
October 11, 2024
FDA Approves Inavolisib Combination in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
The ASCO Post
October 09, 2024
DESTINY-Breast12: T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
The ASCO Post
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
October 02, 2024
ACS Report: Despite Overall Decreases in Breast Cancer Mortality, Incidence Rising in Key Groups
The ASCO Post
October 01, 2024
Neo-CheckRay: Adding Durvalumab to Neoadjuvant Regimen Improves Pathologic Complete Response Rate in High-Risk Breast Cancer
The ASCO Post
September 26, 2024
Quality-of-Life Outcomes: Whole-Breast Irradiation vs Accelerated Partial-Breast Irradiation Following Breast-Conserving Surgery
The ASCO Post
Advertisement
Recommendations
Advertisement